HotSpot Therapeutics, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Mersana Ends 2022 With Third Big Pharma

Jonathan Behr, a US partner at the Dementia Discovery Fund (DDF), sees the increase during the past few years in early-stage investments in neurodegeneration-focused biopharmaceutical companies having

Atea Pharmaceuticals Inc. has been quietly developing a pipeline of oral direct-acting antiviral drugs against hepatitis C and other RNA viruses since 2014, but now the company has emerged from steal

Investors can't seem to get enough of biopharmaceutical companies developing drugs for non-alcoholic steatohepatitis (NASH), an indication with potentially millions of patients, no approved therapies